products medicine-safety health-literacy 
pharmaphorum
OCTOBER 2, 2020
New research shows that the COVID-19 pandemic is encouraging people to take their health into their own hands, and experts say this trend towards self-care could be a significant boon for healthcare systems – one the pharma industry should be encouraging. People are going to have to start taking ownership of their own health.
pharmaphorum
AUGUST 24, 2020
With our understanding of cancer accelerating at an unprecedented rate, and personalised medicines on the cusp of becoming mainstream, regulatory bodies need new ways to assess products. . He added that it allowed people to provide information on their trial experience in a relatable, accessible manner. . “The
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JULY 26, 2021
A lack of racial diversity in clinical trials is a long-standing, well-documented problem that contributes to the stark health inequalities that have been brought into sharp focus by COVID-19. The principles are an important step toward greater health equity,” said Stephen J. Ubl, president and chief executive officer at PhRMA. “We
Delveinsight
FEBRUARY 17, 2021
Almost all the aspects of the healthcare sector, such as service delivery, communications, operation, medical equipment, and drug development, have grown remarkably and improved the overall health outcome. Besides it is in use to analyze population health trends, medical records, virtual nursing assistants, and administrative work.
Delveinsight
FEBRUARY 3, 2021
In the economy, fake news can fluctuate the stock market and currency of a country, economic growth, consumers perception and decision-making toward products and companies. Health rumours and unverified information and claims can cause more havoc to public health and safety. What happened due to fake news in healthcare?
Drug Discovery World
JANUARY 5, 2023
Greater data-centricity, supported by new technologies, is key to driving efficient product approvals and supply chains. In the past two years, EU regulatory authorities accelerated processes so that vaccines and medicines could be brought to market more quickly. This isn’t just about approving new products more swiftly.
Pharma Marketing Network
APRIL 30, 2021
While the lack of racial and ethnic diversity in trials has been apparent for some time, it’s been brought into sharper focus by the COVID-19 pandemic, which severely impacted those communities and exacerbated pre-existing disparities in access to health care. They will also help to increase the diversity of patients enrolled in trials.
Expert insights. Personalized for you.
109 
Let's personalize your content